|
1
|
NIH Consensus Conference: Adjuvant therapy
for patients with colon and rectal cancer. JAMA. 264:1444–1450.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moertel CG, Fleming TR, Macdonald JS, et
al: Fluorouracil plus levamisole as effective adjuvant therapy
after resection of stage III colon carcinoma: a final report. Ann
Intern Med. 122:321–326. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sargent DJ, Goldberg RM, Jacobson SD, et
al: A pooled analysis of adjuvant chemotherapy for resected colon
cancer in elderly patients. N Engl J Med. 345:1091–1097. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gill S, Loprinzi CL, Sargent DJ, et al:
Pooled analysis of fluorouracil-based adjuvant therapy for stage II
and III colon cancer: who benefits and by how much? J Clin Oncol.
22:1797–1806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Cancer Institute: Colon and
Rectal cancer Treatment. http://www.cancer.gov/cancertopics/treatment/colon-and-rectal.
Accessed September 16, 2012.
|
|
6
|
O’Connell MJ, Martenson JA, Wieand HS, et
al: Improving adjuvant therapy for rectal cancer by combining
protracted-infusion fluorouracil with radiation therapy after
curative surgery. N Engl J Med. 331:502–507. 1994.PubMed/NCBI
|
|
7
|
Figueredo A, Charette ML, Maroun J,
Brouwers MC and Zuraw L: Adjuvant therapy for stage II colon
cancer: a systematic review from the Cancer Care Ontario Program in
evidence-based care’s gastrointestinal cancer disease site group. J
Clin Oncol. 22:3395–3407. 2004.
|
|
8
|
Benson AB III, Schrag D, Somerfield MR, et
al: American Society of Clinical Oncology recommendations on
adjuvant chemotherapy for stage II colon cancer. J Clin Oncol.
22:3408–3419. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sargent DJ, Wieand HS, Haller DG, et al:
Disease-free survival versus overall survival as a primary end
point for adjuvant colon cancer studies: individual patient data
from 20,898 patients on 18 randomized trials. J Clin Oncol.
23:8664–8670. 2005. View Article : Google Scholar
|
|
10
|
Goldberg RM, Tabah-Fisch I, Bleiberg H, et
al: Pooled analysis of safety and efficacy of oxaliplatin plus
fluorouracil/leucovorin administered bimonthly in elderly patients
with colorectal cancer. J Clin Oncol. 24:4085–4091. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
André T, Boni C, Navarro M, et al:
Improved overall survival with oxaliplatin, fluorouracil, and
leucovorin as adjuvant treatment in stage II or III colon cancer in
the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009.PubMed/NCBI
|
|
12
|
Schrag D, Rifas-Shiman S, Saltz L, Bach PB
and Begg CB: Adjuvant chemotherapy use for Medicare beneficiaries
with stage II colon cancer. J Clin Oncol. 20:3999–4005. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O’Connor ES, Greenblatt DY, LoConte NK, et
al: Adjuvant chemotherapy for stage II colon cancer with poor
prognostic features. J Clin Oncol. 29:3381–3388. 2011.PubMed/NCBI
|
|
14
|
Silberfarb PM, Philibert D and Levine PM:
Psychosocial aspects of neoplastic disease: II. Affective and
cognitive effects of chemotherapy in cancer patients. Am J
Psychiatry. 137:597–601. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oxman TE and Silberfarb PM: Serial
cognitive testing in cancer patients receiving chemotherapy. Am J
Psychiatry. 137:1263–1265. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Devlen J, Maguire P, Phillips P and
Crowther D: Psychological problems associated with diagnosis and
treatment of lymphomas. II: Prospective study. Br Med J.
295:955–957. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Parth P, Dunlap WP, Kennedy RS, et al:
Motor and cognitive testing of bone marrow transplant patients
after chemoradiotherapy. Percept Mot Skills. 68:1227–1241. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Copeland DR, Moore BD III, Francis DJ, et
al: Neuropsy-chologic effects of chemotherapy on children with
cancer: a longitudinal study. J Clin Oncol. 14:2826–2835.
1996.PubMed/NCBI
|
|
19
|
Waber DP, Tarbell NJ, Fairclough D, et al:
Cognitive sequelae of treatment in childhood acute lymphoblastic
leukemia: cranial radiation requires an accomplice. J Clin Oncol.
13:2490–2496. 1995.PubMed/NCBI
|
|
20
|
Ahles TA, Silberfarb PM, Rundle AC, et al:
Quality of life in patients with limited small-cell carcinoma of
the lung receiving chemotherapy with or without radiation therapy,
for cancer and Leukemia Group B. Psychother Psychosom. 62:193–199.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wieneke MH and Dienst ER:
Neuropsychological assessment of cognitive functioning following
chemotherapy for breast cancer. Psychooncology. 4:61–66. 1995.
View Article : Google Scholar
|
|
22
|
Meyers CA, Byrne KS and Komaki R:
Cognitive deficits in patients with small cell lung cancer before
and after chemotherapy. Lung Cancer. 12:231–235. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schwartz CL: Late effects of treatment in
long-term survivors of cancer. Cancer Treat Rev. 21:355–366. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Dam FS, Schagen SB, Muller MJ, et al:
Impairment of cognitive function in women receiving adjuvant
treatment for high-risk breast cancer: high-dose versus
standard-dose chemotherapy. J Natl Cancer Inst. 90:210–218.
1998.PubMed/NCBI
|
|
25
|
Schagen SB, van Dam FS, Muller MJ, et al:
Cognitive deficits after postoperative adjuvant chemotherapy for
breast carcinoma. Cancer. 85:640–650. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schagen SB, Hamburger HL, Muller MJ, et
al: Neurophysiological evaluation of late effects of adjuvant
high-dose chemotherapy on cognitive function. J Neurooncol.
51:159–165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schagen SB, Muller MJ, Boogerd W, et al:
Change in cognitive function after chemotherapy: a prospective
longitudinal study in breast cancer patients. J Natl Cancer Inst.
98:1742–1745. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kreukels BP, van Dam FS, Ridderinkhof KR,
et al: Persistent neurocognitive problems after adjuvant
chemotherapy for breast cancer. Clin Breast Cancer. 8:80–87. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brezden CB, Phillips KA, Abdolell M, et
al: Cognitive function in breast cancer patients receiving adjuvant
chemotherapy. J Clin Oncol. 18:2695–2701. 2000.PubMed/NCBI
|
|
30
|
Wefel JS, Lenzi R, Theriault RL, Davis RN
and Meyers CA: The cognitive sequelae of standard-dose adjuvant
chemotherapy in women with breast carcinoma: results of a
prospective, randomized, longitudinal trial. Cancer. 100:2292–2299.
2004. View Article : Google Scholar
|
|
31
|
Hurria A, Rosen C, Hudis C, et al:
Cognitive function of older patients receiving adjuvant
chemotherapy for breast cancer: a pilot prospective longitudinal
study. J Am Geriatr Soc. 54:925–931. 2006. View Article : Google Scholar
|
|
32
|
Deprez S, Amant F, Smeets A, et al:
Longitudinal assessment of chemotherapy-induced structural changes
in cerebral white matter and its correlation with impaired
cognitive functioning. J Clin Oncol. 30:274–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Heck JE, Albert SM, Franco R and Gorin SS:
Patterns of dementia diagnosis in surveillance, epidemiology, and
end results breast cancer survivors who use chemotherapy. J Am
Geriatr Soc. 56:1687–1692. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baxter NN, Durham SB, Phillips KA,
Habermann EB and Virning BA: Risk of dementia in older breast
cancer survivors: a population-based cohort study of the
association with adjuvant chemotherapy. J Am Geriatr Soc.
57:403–411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Raji MA, Tamborello LP, Kuo YF, Ju H,
Freeman JL, Zhang DD, Giordano SH and Goodwin JS: Risk of
subsequent dementia diagnoses does not vary by types of adjuvant
chemotherapy in older women with breast cancer. Med Oncol.
26:452–459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Du XL, Xia R and Hardy D: Relationship
between chemotherapy use and cognitive impairments in older women
with breast cancer: findings from a large population-based cohort.
Am J Clin Oncol. 33:533–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
National Cancer Institute: About the SEER
(Surveillance Epidemiology and End Results) Registries. http://seer.cancer.gov/registries/.
Accessed September 15, 2012.
|
|
38
|
Warren JL, Klabunde CN, Schrag D, Bach PB
and Riley GF: Overview of the SEER-Medicare data: content, research
applications, and generalizability to the United States elderly
population. Med Care. 40(Suppl): 3–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Parsons LS: Reducing Bias in a Propensity
Score Matching-Pair Sample Using GreedyMatching Techniques.
available at http://www2.sas.com/proceedings/sugi26/p214-26.pdf.
Accessed July 2, 2012.
|
|
40
|
Du XL and Goodwin JS: Patterns of use of
chemotherapy for breast cancer in older women: findings from
Medicare claims data. J Clin Oncol. 19:1455–1461. 2001.PubMed/NCBI
|
|
41
|
Warren JL, Harlan LC, Fahey A, et al:
Utility of the SEER-Medicare data to identify chemotherapy use. Med
Care. 40:IV-55–IV-61. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Du XL, Key CR, Dickie L, et al: External
validation of medicare claims for breast cancer chemotherapy
compared with medical chart reviews. Med Care. 44:124–131. 2006.
View Article : Google Scholar
|
|
43
|
Lamont EB, Herndon JE II, Weeks JC, et al:
Criterion validity of Medicare chemotherapy claims in cancer and
leukemia Group B breast and lung cancer trial participants. J Natl
Cancer Inst. 97:1080–1083. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liang SY, Phillips KA, Wang G, et al:
Tradeoffs of using administrative claims and medical records to
identify the use of personalized medicine for patients with breast
cancer. Med Care. 49:e1–e8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lund JL, Stürmer T, Harlan LC, et al:
Identifying specific chemotherapeutic agents in medicare data: a
validation study. Med Care. Nov 10–2011, (Epub ahead of print).
|
|
46
|
US Public Health Services: International
Classification of Diseases, 9th Revision, Clinical Modification.
5th edition. Practice Management Information Corp.; Los Angeles,
CA: 1996
|
|
47
|
American Medical Association: Physicians’
Current Procedural Terminology-CPT 2000. American Medical
Association; Chicago, IL: 2000
|
|
48
|
Health Care Financing Administration: HCFA
Common Procedure Coding System: National Level II Medicare Codes.
Practice Management Information Corp.; Los Angeles, CA: 2000
|
|
49
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Romano PS, Roos LL and Jollis JG: Adapting
a clinical comorbidity index for use with ICD-9-CM administrative
data: differing perspectives. J Clin Epidemiol. 46:1075–1079. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Klabunde CN, Potosky AL, Legler JM and
Warren JL: Development of a comorbidity index using physician
claims data. J Clin Epidemiol. 53:1258–1267. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
National Cancer Institute: SEER-Medicare:
Calculation of Comorbidity Weights. http://healthservices.cancer.gov/seermedicare/program/comorbidity.html.
Accessed July 18, 2012.
|
|
53
|
Penman AD and Johnson WD: A SAS program
for calculating cumulative incidence of events (with confidence
limits) and number at risk at specified time intervals with
partially censored data. Comput Methods Programs Biomed. 89:50–55.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Allison PD: Survival Analysis Using the
SAS System: A Practical Guide. SAS Institute Inc; Cary, NC:
1995
|
|
55
|
Ahles TA and Saykin AJ: Candidate
mechanisms for chemotherapy-induced cognitive changes. Nat Rev
Cancer. 7:192–201. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
56
|
Long JM, Lee GD, Kelley-Bell B, Spangler
EL, Perez EJ, Longo DL, de Cabo R, Zou S and Rapp PR: Preserved
learning and memory following 5-fluorouracil and cyclophosphamide
treatment in rats. Pharmacol Biochem Behav. 100:205–211. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Fremouw T, Fessler CL, Ferguson RJ and
Burguete Y: Preserved learning and memory in mice following
chemotherapy: 5-fluorouracil and doxorubicin single agent
treatment, doxorubicin-cyclophosphamide combination treatment.
Behav Brain Res. 226:154–162. 2012. View Article : Google Scholar
|
|
58
|
Fardell JE, Vardy J, Shah JD and Johnston
IN: Cognitive impairments caused by oxaliplatin and 5-fluorouracil
chemotherapy are ameliorated by physical activity.
Psychopharmacology. 220:183–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Christie LA, Acharya MM, Parihar VK,
Nguyen A, Martirosian V and Limoli CL: Impaired cognitive function
and hippocampal neurogenesis following cancer chemotherapy. Clin
Cancer Res. 18:1954–1965. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Winocur G, Henkelman M, Wojtowicz JM,
Zhang H, Binns MA and Tannock IF: The effects of chemotherapy on
cognitive function in a mouse model: a prospective study. Clin
Cancer Res. 18:3112–3121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Byers AL and Yaffe K: Depression and risk
of developing dementia. Nat Rev Neurol. 7:323–331. 2011. View Article : Google Scholar : PubMed/NCBI
|
